Table 2.
Results of the subdistribution hazard regression (Fine and Gray) models for both type of failures
| Unadjusted | Adjustedc | |||
|---|---|---|---|---|
| Patient categories | SDHR (95 % CI)b | P value | SDHR (95 % CI)b | P value |
| CSM | ||||
| Agea | 0.96 (0.75–1.23) | 0.121 | 0.95 (0.67–1.35) | 0.132 |
| Stage | ||||
| III | 1 | 1 | ||
| IV | 2.43 (1.58–3.73) | 0.026 | 2.66 (1.47–4.81) | 0.021 |
| Grade | ||||
| 1 | 1 | 1 | ||
| 2 | 1.24 (0.97–1.59) | 0.037 | 1.36 (0.99–1.94) | 0.088 |
| 3 | 1.57 (1.03–2.39) | 0.024 | 1.89 (1.04–3.43) | 0.031 |
| Histology | ||||
| Serous | 1 | 1 | ||
| Mucinous | 0.93 (0.82–1.05) | 0.095 | 0.95 (0.79–1.14) | 0.118 |
| Clear cell | 1.43 (1.02–2.01) | 0.036 | 1.68 (1.14–2.48) | 0.029 |
| Endometrioid | 0.96 (0.82–1.12) | 0.102 | 0.98 (0.89–1.07) | 0.095 |
| Othersd | 2.17 (1.65–2.85) | 0.028 | 2.36 (1.67–3.34) | 0.025 |
| Type of chemotherapy | ||||
| intravenous | 1 | 1 | ||
| intraperitoneal | 0.78 (0.67–0.91) | 0.029 | 0.82 (0.70–0.96) | 0.031 |
| GOG performance status | ||||
| ≤ 1 | 1 | 1 | ||
| ≥ 2 | 0.83 (0.68–1.02) | 0.075 | 0.92 (0.81–1.06) | 0.079 |
| Charlson comorbidity index | ||||
| 0 | 1 | 1 | ||
| ≥ 1 | 0.84 (0.68–1.04) | 0.083 | 0.88 (0.70–1.09) | 0.089 |
| OCM | ||||
| Agea | 0.95 (0.91–0.99) | 0.038 | 0.92 (0.87–0.97) | 0.017 |
| Stage | ||||
| III | 1 | 1 | ||
| IV | 0.92 (0.77–1.11) | 0.337 | 0.87 (0.69–1.04) | 0.214 |
| Grade | ||||
| 1 | 1 | 1 | ||
| 2 | 0.87 (0.65–1.16) | 0.298 | 0.91 (0.64–1.29) | 0.348 |
| 3 | 0.92 (0.59–1.47) | 0.361 | 0.87 (0.55–1.37) | 0.229 |
| Histology | ||||
| Serous | 1 | 1 | ||
| Mucinous | 1.06 (0.89–1.26) | 0.139 | 1.07 (0.85–1.35) | 0.168 |
| Clear cell | 1.01 (0.76–1.18) | 0.106 | 1.05 (0.86–1.28) | 0.143 |
| Endometrioid | 0.95 (0.82–1.10) | 0.295 | 0.98 (0.79–1.21) | 0.315 |
| Othersd | 0.91 (0.81–1.02) | 0.082 | 0.89 (0.75–1.05) | 0.091 |
| Type of chemotherapy | ||||
| Intravenous | 1 | 1 | ||
| Intraperitoneal | 0.89 (0.73–1.22) | 0.127 | 0.94 (0.81–1.09) | 0.115 |
| GOG performance status | ||||
| ≤ 1 | 1 | 1 | ||
| ≥ 2 | 1.05 (0.84–1.38) | 0.229 | 1.03 (0.82–1.36) | 0.226 |
| Charlson comorbidity index | ||||
| 0 | 1 | 1 | ||
| ≥ 1 | 0.77 (0.65–0.92) | 0.022 | 0.79 (0.66–0.94) | 0.027 |
Abbreviations CSM cancer-specific mortality, OCM other-cause mortality, CI confidence interval
aper 10 year increment in age
bSDHR denotes subdistribution hazards ratio obtained by Fine-Gray model. CI, confidence interval
cAdjusted for the following factors: age, stage, nuclear grade, histologic subtype, type of chemotherapy
d“Others” histology includes mixed type, undifferentiated, and carcinosarcoma